|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2003-4-30
|
|
pubmed:abstractText |
A meta-analysis of randomized trials in advanced ovarian cancer showed a longer survival with cyclophosphamide, doxorubicin, and cisplatin (CAP) than with cyclophosphamide and cisplatin (CP; P =.009). In contrast, the results of the large International Collaborative Ovarian Neoplasm Study (ICON2) showed no survival difference between CAP and carboplatin (P =.98). In this article, we show how these discrepant results can be reconciled through the estimation of expected survival curves.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BurzykowskiTomaszT,
pubmed-author:BuyseMarcM,
pubmed-author:ColomboNicolettaN,
pubmed-author:ContePierfrancoP,
pubmed-author:International Collaborative Ovarian Neoplasm Collaborators,
pubmed-author:OmuraGeorgeG,
pubmed-author:Ovarian Cancer Meta-Analysis Project,
pubmed-author:ParmarMaheshM,
pubmed-author:TorriValterV,
pubmed-author:VermorkenJanJ,
pubmed-author:WilliamsChrisC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1682-7
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12721242-Adult,
pubmed-meshheading:12721242-Aged,
pubmed-meshheading:12721242-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12721242-Cisplatin,
pubmed-meshheading:12721242-Cyclophosphamide,
pubmed-meshheading:12721242-Doxorubicin,
pubmed-meshheading:12721242-Female,
pubmed-meshheading:12721242-Humans,
pubmed-meshheading:12721242-Middle Aged,
pubmed-meshheading:12721242-Models, Statistical,
pubmed-meshheading:12721242-Ovarian Neoplasms,
pubmed-meshheading:12721242-Prognosis,
pubmed-meshheading:12721242-Randomized Controlled Trials as Topic,
pubmed-meshheading:12721242-Reproducibility of Results,
pubmed-meshheading:12721242-Survival
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer.
|
|
pubmed:affiliation |
ScD, International Drug Development Institute Inc, American Twine Office Park, 222 Third St, Suite 0342, Cambridge, MA 02142, USA. marc.buyse@iddi.com
|
|
pubmed:publicationType |
Journal Article,
Meta-Analysis
|
